Technology Listings


36 Results Sort By:
Live Attenuated Zika Virus Vaccines
Application Yellow fever virus-based live attenuated Zika virus (ZIKV) vaccines. Key Benefits Reduces neurotropism from Zika virus. High safety and immunogenicity of chimeric vaccines. Market Summary Zika virus (ZIKV) belongs to the flavivirus family of viruses, which include West Nile (WN), Japanese encephalitis (JE), yellow fever (YF), dengue...
Published: 11/2/2020       Contributor(s): Baek Kim
Live Attenuated Zika Virus Vaccines
Application Yellow fever virus-based live attenuated Zika virus (ZIKV) vaccines. Key Benefits Reduces neurotropism from Zika virus. High safety and immunogenicity of chimeric vaccines. Market Summary Zika virus (ZIKV) belongs to the flavivirus family of viruses, which include West Nile (WN), Japanese encephalitis (JE), yellow fever (YF), dengue...
Published: 7/1/2020       Contributor(s): Baek Kim
Boosting Immunogenicity of Vaccines Using Saponins and Agonists of the Intracellular STING Pathway
Application Vaccine formulation of an activator of the stimulator of interferon genes (STING) pathway and saponin adjuvant for enhanced protection of aged population. Key Benefits Significantly improved protective immunity of vaccine in the aged. More efficient than the current methods of influenza vaccination of population 65 years of age or...
Published: 4/24/2020       Contributor(s): Elena Vassilieva, Richard Compans
Virus-Like Particles as RSV Vaccine Candidate
Application Virus-like particle (VLP) vaccine candidate(s) to prevent respiratory syncytial virus (RSV) infection. Key Benefits Candidates may have the most effective anti-viral and anti-inflammatory response. Potentially protects elderly and immunocompromised patients from re-infection with the RSV virus. Efficient, tunable and stable production...
Published: 1/15/2020       Contributor(s): Binh Ha, Larry Anderson, Elizabeth Wright
Trimeric Immunogen for HIV-1 Vaccination
Application Trimeric gp120 immunogen that induces broadly cross-reactive V1V2-antibodies for HIV-1 vaccine. Key Benefits Possible oral administration. Broadly cross-reactive against HIV-1 panel. Promotes antibody responses as both a primary immunogen and boosting immunogen. Market Summary Antiretroviral therapy (ART) has dramatically prolonged...
Published: 8/26/2019       Contributor(s): Rama Amara, Andrew Jones, Raghavan Varadarajan, Sannula Kesavardhana
Glycoprotein Tetramer for Identifying Antigen-specific B Cells
ApplicationEctodomain of viral glycoprotein tetramers detects antigen-specific memory B Cells.Key BenefitsViral glycoprotein tetramers detect antigen-specific memory B cells in the peripheral blood and tissues.Hepatitis C virus E2 protein triggers immune response, which may yield an effective vaccine against hepatitis C virus.Market SummaryHepatitis...
Published: 5/9/2019       Contributor(s): Arash Grakoui, Joseph Marcotrigiano
ReadyVax
ApplicationStandalone smartphone app to increase vaccinations and improve vaccine knowledge for providers, pharmacists, and the general public.Key BenefitsProvides detailed information about a variety of vaccines and diseases. Sends out alerts and updates. Market SummaryVaccines prevent millions of cases of infectious diseases each year; however, many...
Published: 4/2/2019       Contributor(s): Saad Omer, Robert Bednarczyk, Paula Frew, Walter Orenstein, Ines Gonzalez-Casanova, Neal Halsey, Daniel Salmon
Human Monoclonal Antibodies Against Ebola Virus
ApplicationAntibodies that bind and neutralize Ebola virus glycoprotein (GP) for use in vaccination or treatment of Ebola virus disease.Key BenefitsHigher binding affinity for Ebola virus GP than closest competitor.Can be used prophylactically or for treatment of Ebola virus disease.Market SummaryThe Ebola virus is an RNA virus with a membrane composed...
Published: 3/26/2019       Contributor(s): Rafi Ahmed
Respiratory Syncytial Virus (RSV) A2 Expressing Firefly Luciferase
ApplicationRecombinant RSV strain expressing firefly luciferase and the F & G genes from clinical strain A2001/2-20 for research and development of vaccines.Key BenefitsF & G proteins included in this strain show different behavior than those of the typical A2 strain proteins.May be adapted in a variety of assays, enabling the identification...
Published: 2/19/2017       Contributor(s): Martin Moore, Christopher Stobart
Helper Plasmids for Rescue of Respiratory Syncytial Virus
ApplicationPlasmids rescuing recombinant syncytial virus for RSV research and vaccine development.Key BenefitsAllow expression and recombination in vero cells.Optimized for human codon bios to increase expression in mammalian cells.Market SummaryRespiratory syncytial virus (RSV) is the major cause of acute lower respiratory tract infections in infants...
Published: 2/16/2017       Contributor(s): Martin Moore
1 2 3 4